An introduction to the Marburg virus vaccine consortium, MARVAC
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
PLoS pathogens - 18(2022), 10 vom: 13. Okt., Seite e1010805 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 17.10.2022 Date Revised 06.09.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.ppat.1010805 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347429505 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347429505 | ||
| 003 | DE-627 | ||
| 005 | 20231226033813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.ppat.1010805 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347429505 | ||
| 035 | |a (NLM)36227853 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cross, Robert W |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An introduction to the Marburg virus vaccine consortium, MARVAC |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2022 | ||
| 500 | |a Date Revised 06.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Longini, Ira M |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Bok, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, David |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Miles W |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Janet V |e verfasserin |4 aut | |
| 700 | 1 | |a Dowling, William E |e verfasserin |4 aut | |
| 700 | 1 | |a Draghia-Akli, Ruxandra |e verfasserin |4 aut | |
| 700 | 1 | |a Duworko, James T |e verfasserin |4 aut | |
| 700 | 1 | |a Dye, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Egan, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Fast, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Finan, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Finch, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming, Thomas R |e verfasserin |4 aut | |
| 700 | 1 | |a Fusco, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Geisbert, Thomas W |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Günther, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Hensley, Lisa E |e verfasserin |4 aut | |
| 700 | 1 | |a Honko, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Hunegnaw, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Jakubik, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Ledgerwood, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Luhn, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Matassov, Demetrius |e verfasserin |4 aut | |
| 700 | 1 | |a Meshulam, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Emily V |e verfasserin |4 aut | |
| 700 | 1 | |a Parks, Christopher L |e verfasserin |4 aut | |
| 700 | 1 | |a Rustomjee, Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Safronetz, David |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Lauren M |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Smock, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Sow, Ydrissa |e verfasserin |4 aut | |
| 700 | 1 | |a Spiropoulou, Christina F |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Nancy J |e verfasserin |4 aut | |
| 700 | 1 | |a Warfield, Kelly L |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfe, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Woolsey, Courtney |e verfasserin |4 aut | |
| 700 | 1 | |a Zahn, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Henao-Restrepo, Ana María |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Fontela, César |e verfasserin |4 aut | |
| 700 | 1 | |a Marzi, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLoS pathogens |d 2005 |g 18(2022), 10 vom: 13. Okt., Seite e1010805 |w (DE-627)NLM158124782 |x 1553-7374 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:10 |g day:13 |g month:10 |g pages:e1010805 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.ppat.1010805 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 10 |b 13 |c 10 |h e1010805 | ||